Neurology reimbursement alerts

Xeomin (incobotulinumtoxinA) is an injectable botulinum toxin type A administered via injection, placing it squarely in the Medicare Part B pathway for physician-administered drugs. It is reimbursed u

Enspryng (Satralizumab) is an injectable drug approved for Part B billing, likely leading to a new J-code assignment. With its status as an orphan drug, it may qualify for pass-through payment under M

Emgality (galcanezumab) is likely to receive a new J-code for billing under Medicare Part B since it is an injectable drug. The drug may be eligible for ASP+6% reimbursement, given its injectable stat

VYEPTI (Eptinezumab-JJMR) is an injectable medication likely to receive a J-code for billing under Medicare Part B. Its category may allow for ASP+6% reimbursement, but billing teams should confirm th

Epidiolex, an oral cannabidiol solution, will fall under Medicare Part D for billing purposes. As it is an orphan drug, it may also have specific considerations for reimbursement and coverage. No J-co

Ajovy (fremanezumab-vfrm), an injectable drug approved by the FDA, is expected to receive a J-code assignment for Medicare billing. It is likely to be reimbursed under Part B, potentially utilizing an

The proposed LCD for automated MRI detection and quantification could streamline billing for neurology services, potentially improving efficiency and accuracy in claims processing. This could lead to

The proposed LCD for MRgFUS for tremor could significantly impact billing by introducing clear guidelines for coverage and reimbursement rates. This advancement may encourage more providers to offer t

The proposed LCD DL33398 for Transcranial Magnetic Stimulation is currently open for comments until the deadline. Providers are encouraged to review the draft to assess its potential billing impacts.

The implementation of the LCD for molecular testing in hereditary transthyretin amyloidosis requires billing team review. Providers should be aware of the guide

LCD L33398 governs coverage of Transcranial Magnetic Stimulation (TMS) under National Government Services jurisdiction, with the current notice period ending 08/08/2026 and the new policy becoming eff

The introduction of LCD for HLA-DQB1*06:02 testing for narcolepsy may affect billing practices by requiring updated coding and documentation specific to the new guidelines. Providers will need to fami

The new LCD for Transcranial Magnetic Stimulation (TMS) will outline coverage specifics which may influence the billing practices for Neurology specialists. Providers should prepare for potential adju

The new LCD for Transcranial Magnetic Stimulation (TMS) by Noridian could significantly impact billing practices for Neurology specialists. Effective from 08/20/2023, providers need to ensure complian

The new LCD for Somatosensory Testing establishes specific guidelines that may affect reimbursement rates for this service. Providers will need to ensure they meet the outlined criteria to secure prop

The introduction of the MRgFUS system for neurologic conditions may significantly impact billing practices due to its innovative approach and potential for improved patient outcomes. As this technolog

The implementation of MRgFUS for treating Essential Tremor and tremor-dominant Parkinson's Disease is affecting compliance updates. It opens the door for additional reimbursements under Medica

The upcoming LCD for Polysomnography and Other Sleep Studies may significantly influence billing practices, as it will provide updated indications and coverage criteria for sleep study services. Provi

The introduction of the Computed Tomography Cerebral Perfusion Analysis (CTP) under Noridian may increase compliance updates for neurological evaluations. Providers should ensure proper documentati

The introduction of MRgFUS for treating essential tremor and tremor dominant Parkinson's disease may lead to increased compliance updates for facilities that provide this service. As reimbursement

The LCD for Polysomnography and Other Sleep Studies by Noridian will likely impact billing practices by providing updated guidelines and criteria on the utilization of sleep study tests. Providers wil

The new LCD for Nerve Conduction Studies and Electromyography will have significant billing implications for practices performing these services. Providers will need to closely adhere to the updated g

The introduction of Autonomic Function Testing as a covered service will likely enhance compliance updates for providers in Neurology, who can now integrate this test into their diagnostic protocol

The LCD for Nerve Conduction Studies and Electromyography emphasizes the need for proper documentation and adherence to indicated criteria for reimbursement. As such, providers must ensure compliance

The new LCD on Automated Detection and Quantification of Brain MRIs is projected to supports compliance with updated rates processes by providing clear guidelines for billing these advanced imaging services. Providers

The new LCD for Intraoperative Neurophysiological Testing effective January 1, 2026, will likely impact billing practices by defining specific criteria for coverage and reimbursement. Providers must f

The introduction of MRgFUS for tremor will provide compliance updates under Medicare, particularly for outpatient services. Providers should prepare for potential claims adjustments as local co

The implementation of HLA-DQB1*06:02 testing for Narcolepsy will enable better diagnostic precision for patients, potentially increasing appropriate billing for covered tests. Clinicians who incorpora

The introduction of LCD for HLA-DQB1*06:02 testing will provide clearer billing guidelines for narcolepsy diagnostics, potentially increasing the appropriateness of claims submissions. It could lead t

The implementation of the new LCD for Non-Invasive Cerebrovascular Studies by WPS could significantly impact reimbursement rates for related services. Healthcare providers will need to ensure complian

The new LCD on polysomnography and other sleep studies may impact billing by clarifying the criteria for coverage, which could either improve claim approval rates or increase denials if not followed c

The upcoming LCD on Hypoglossal Nerve Stimulation will affect billing practices for sleep apnea treatment services. Providers must ensure they are familiar with the guidelines to avoid claim denials o

The LCD for Immune Globulin Intravenous (IVIg) by Noridian outlines the specific eligibility criteria and documentation requirements for reimbursement. It is crucial for providers to ensure compliance

The upcoming LCD for Transcranial Magnetic Stimulation (TMS) effective from March 26, 2026, may significantly impact billing by potentially introducing new coverage criteria and reimbursement rates. P

The upcoming Local Coverage Determination (LCD) for Hypoglossal Nerve Stimulation will impact billing practices significantly by introducing specific codes and guidelines starting March 26, 2026. Prov

The introduction of the LCD for somatosensory testing by CGS may lead to increased scrutiny of claims related to this service. Providers must ensure that they are meeting the new documentation require

The final LCD L35897 pertains to Nerve Conduction Studies and Electromyography, effective from May 7, 2026. This indicates that providers in Kentucky and Ohio should prepare for potential changes in b